|Bid||59.50 x 200|
|Ask||72.99 x 200|
|Day's Range||72.04 - 73.40|
|52 Week Range||42.62 - 81.91|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||75.72|
NEW YORK, April 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Stock Monitor: Cancer Genetics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 10, 2018 / Active-Investors.com has just released a free earnings report on DexCom, Inc. (NASDAQ: DXCM ). If you want ...
DexCom, Inc. today announced that it plans to release its first quarter 2018 financial results after market close on Wednesday, May 2, 2018. Management will hold a conference call to review the company's first quarter 2018 performance starting at 4:30 p.m.
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a pharmacy operator's stock.
DexCom, Inc. , the leader in continuous glucose monitoring is pleased to announce that the U.S. Food and Drug Administration has granted a De Novo request for the Dexcom G6® CGM System, the newest generation of CGM for people with diabetes ages 2 and up.
The U.S. Food and Drug Administration on Tuesday approved DexCom Inc's monitoring system to check blood sugar levels in children and adults suffering from diabetes, which can be used along with devices such as insulin pumps. This is the first glucose monitoring system permitted by the agency that can be used with other compatible medical devices, the FDA said. A previous version of DexCom's monitoring system had received FDA approval in 2016 but was not designed to be used with other devices.
NEW YORK, NY / ACCESSWIRE / March 26, 2018 / Rising concerns over a potential trade war with China continued to drag markets down on Friday, with the Dow Jones plummeting more than 400 points. The Dow ...
On February 26, 2018, Medtronic (MDT) announced that the FDA has approved a new arm indication for its Guardian Sensor 3, the latest and most accurate CGM (continuous glucose monitoring) sensor. The expanded indication will enable the sensor to be worn on the upper arm, thus providing more flexibility, higher accuracy, and enhanced performance. It is the only sensor approved for use with Medtronic’s MiniMed 670G, which is the first HCL (hybrid closed loop) insulin delivery system in the world.
On February 21, 2018, Medtronic (MDT) announced the launch of its MiniMed Mio Advance infusion set, the newest addition to its portfolio of MiniMed infusion sets. The device is used for insulin delivery from an insulin pump to a person’s body. In late 2018, Medtronic plans to expand the commercial availability of the device in other geographies around the world.
The US Patent Office Patent Trial and Appeal Board recently ruled to uphold the validity of WaveForm Technologies Inc. patents in the emerging field of continuous glucose monitoring SALEM, N.H. and WILSONVILLE, ...
The San Diego-based company said it had a loss of 11 cents per share. Earnings, adjusted for pretax expenses, were 10 cents per share. The results beat Wall Street expectations. The average estimate of ...
DexCom, Inc. today reported its financial results as of and for the quarter and fiscal year ended December 31, 2017.
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / DexCom, Inc. (NASDAQ: DXCM ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 4:30 PM Eastern Time. ...
DexCom (NASDAQ: DXCM ) will be releasing its next round of earnings Tuesday. For all of the relevant information, here is your guide for today's Q4 earnings announcement. Earnings and Revenue Based on ...
The bulls that were plowing into Fitbit Inc (NYSE:FIT) headed into Thursday’s post-close earnings report are likely regretting that decision now. After gaining 5% during regular trading hours, Fitbit stock is now tanking the tune of 13% in pre-market action when disappointing results were underscored by even more disappointing guidance. No. If nothing else, Fitbit is a powerful brand name that will always be able to leveraged somehow.
DexCom Inc (NASDAQ:DXCM), a medical equipment company based in United States, saw significant share price volatility over the past couple of months on the NasdaqGS, rising to the highs ofRead More...
Fitbit shares dropped 13% in after-hours trading on Monday after the company missed on earnings and revenue for its fiscal fourth quarter.
The Soros Fund Management opened up smallish positions in the mid-cap biotechs DexCom and AnaptysBio in the most recent quarter.